Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | EVP and CFO | July 22, 2026 | July 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date July 22, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 305,796 |
Ending reported balance
After 2026-07-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-22 · Exercise / conversion · Acquired 16,296 · Balance 314,115 F1: This acquisition of 16,296 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023. Row 2 · 2026-07-22 · Tax withholding · Disposed 8,319 · Balance 305,796 F2: The exempt disposition of 8,319 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023. |
| Performance RightSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-22 · Exercise / conversion · Disposed 57,381 · Balance 0 F3: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: This acquisition of 16,296 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
F2: The exempt disposition of 8,319 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
F3: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 12, 2018 Filed Aug 22, 2018 23:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionPerformance Right · Derivative | 5,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001675 · doc1.xml · derivative · entry 3 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On July 22, 2015, the reporting person received a target grant of 5,737 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2016, 2017 and 2018. Based on the Company's performance over this period, 3,556 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.exercise_date: On July 22, 2015, the reporting person received a target grant of 5,737 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2016, 2017 and 2018. Based on the Company's performance over this period, 3,556 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.expiration_date: On July 22, 2015, the reporting person received a target grant of 5,737 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2016, 2017 and 2018. Based on the Company's performance over this period, 3,556 shares of Common Stock were issued to the reporting person under this grant. Read SEC document |
| July 12, 2018 Filed Aug 22, 2018 23:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 1,175 | $20.50 | $24,087.50 |
DisclosureSEC source: 0001567619-18-001675 · doc1.xml · nonDerivative · entry 2 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,935 F2 · shares: The exempt disposition of 1,175 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 22, 2015. Read SEC document |
| July 12, 2018 Filed Aug 22, 2018 23:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 3,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001675 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This acquisition of 3,556 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 22, 2015. Read SEC document |
| April 24, 2018 Filed Apr 25, 2018 20:57 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 1,280 | $19.76 | $25,292.80 |
DisclosureSEC source: 0001140361-18-019564 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,172 F1 · shares: The exempt disposition of 1,280 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 24, 2015. Read SEC document |
| August 06, 2017 Filed Aug 8, 2017 21:49 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 495 | $16.56 | $8,197.20 |
DisclosureSEC source: 0001140361-17-030645 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,452 F1 · shares: The exempt disposition of 495 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on August 6, 2013. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantPerformance Right · Derivative | 7,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029081 · doc1.xml · derivative · entry 5 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,409 Underlying: Common Stock · 7,409 shares Expires not disclosed F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,018 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001140361-17-029081 · doc1.xml · derivative · entry 4 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,018 Underlying: Common Stock · 13,018 shares Expires 2027-07-26 F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 3,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029081 · doc1.xml · nonDerivative · entry 3 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,947 F3 · shares: This acquisition of 3,705 shares of Common Stock represents 3,705 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
| July 25, 2017 Filed Jul 28, 2017 19:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 437 | $17.12 | $7,481.44 |
DisclosureSEC source: 0001140361-17-029081 · doc1.xml · nonDerivative · entry 2 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,242 F2 · shares: The exempt disposition of 437 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 25, 2014. Read SEC document |
| July 22, 2017 Filed Jul 28, 2017 19:05 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 397 | $16.80 | $6,669.60 |
DisclosureSEC source: 0001140361-17-029081 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,679 F1 · shares: The exempt disposition of 397 shares of common stock ("Common Stock") of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 20:14 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 1,585 | $15.78 | $25,011.30 |
DisclosureSEC source: 0001140361-17-016719 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,076 F1 · shares: The exempt disposition of 1,585 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 24, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.